-
Mashup Score: 22Biomarkers for response to TIL therapy: a comprehensive review - 1 month(s) ago
Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) has demonstrated durable clinical responses in patients with metastatic melanoma, substantiated by recent positive results of the first phase III trial on TIL therapy. Being a demanding and logistically complex treatment, extensive preclinical and clinical effort is required to optimize patient selection by identifying predictive biomarkers of response. This review aims to comprehensively summarize the current evidence regarding the potential impact of tumor-related factors (such as mutational burden, neoantigen load, immune infiltration, status of oncogenic driver genes, and epigenetic modifications), patient characteristics (including disease burden and location, baseline cytokines and lactate dehydrogenase serum levels, human leucocyte antigen haplotype, or prior exposure to immune checkpoint inhibitors and other anticancer therapies), phenotypic features of the transferred T cells (mainly the total cell count, CD8:CD4
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8
Background Bispecific T-cell engagers (BTEs) are novel agents used to treat hematological malignancies. Early trials were underpowered to define cardiovascular adverse events (CVAE) and no large-scale studies systematically examined the CVAEs associated with BTEs. Methods Leveraging the US Food and Drug Administration’s Adverse Event Reporting System-(FAERS), we identified the relative frequency of CVAEs after initiation of five BTE products approved by the Food and Drug Administration between 2014 and 2023 for the treatment of hematological malignancies. Adjusted reporting ORs (aROR) were used to identify disproportionate reporting of CVAEs with BTEs compared with background rates in the database. Fatality rates and risk ratios (RRs) for each adverse event (AE) were calculated. Results From 3668 BTE-related cases reported to FAERS, 747 (20.4%) involved CVAEs. BTEs as a class were associated with fatal CVAEs (aROR 1.29 (95% CI 1.12 to 1.50)), an association mainly driven by teclistamab
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet-
RT @jitcancer: New #JITC article: Cardiovascular toxicities associated with bispecific T-cell engager therapy https://t.co/bNxSnUotN4 @DrSF…
-
-
Mashup Score: 7
Background Bispecific T-cell engagers (BTEs) are novel agents used to treat hematological malignancies. Early trials were underpowered to define cardiovascular adverse events (CVAE) and no large-scale studies systematically examined the CVAEs associated with BTEs. Methods Leveraging the US Food and Drug Administration’s Adverse Event Reporting System-(FAERS), we identified the relative frequency of CVAEs after initiation of five BTE products approved by the Food and Drug Administration between 2014 and 2023 for the treatment of hematological malignancies. Adjusted reporting ORs (aROR) were used to identify disproportionate reporting of CVAEs with BTEs compared with background rates in the database. Fatality rates and risk ratios (RRs) for each adverse event (AE) were calculated. Results From 3668 BTE-related cases reported to FAERS, 747 (20.4%) involved CVAEs. BTEs as a class were associated with fatal CVAEs (aROR 1.29 (95% CI 1.12 to 1.50)), an association mainly driven by teclistamab
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet-
RT @jitcancer: New #JITC article: Cardiovascular toxicities associated with bispecific T-cell engager therapy https://t.co/bNxSnUotN4 @DrSF…
-
-
Mashup Score: 7
Background Bispecific T-cell engagers (BTEs) are novel agents used to treat hematological malignancies. Early trials were underpowered to define cardiovascular adverse events (CVAE) and no large-scale studies systematically examined the CVAEs associated with BTEs. Methods Leveraging the US Food and Drug Administration’s Adverse Event Reporting System-(FAERS), we identified the relative frequency of CVAEs after initiation of five BTE products approved by the Food and Drug Administration between 2014 and 2023 for the treatment of hematological malignancies. Adjusted reporting ORs (aROR) were used to identify disproportionate reporting of CVAEs with BTEs compared with background rates in the database. Fatality rates and risk ratios (RRs) for each adverse event (AE) were calculated. Results From 3668 BTE-related cases reported to FAERS, 747 (20.4%) involved CVAEs. BTEs as a class were associated with fatal CVAEs (aROR 1.29 (95% CI 1.12 to 1.50)), an association mainly driven by teclistamab
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet-
RT @jitcancer: New #JITC article: Cardiovascular toxicities associated with bispecific T-cell engager therapy https://t.co/bNxSnUotN4 @DrSF…
-
-
Mashup Score: 11Neuroblastoma: an ongoing cold front for cancer immunotherapy - 5 month(s) ago
Neuroblastoma is the most frequent extracranial childhood tumour but effective treatment with current immunotherapies is challenging due to its immunosuppressive microenvironment. Efforts to date have focused on using immunotherapy to increase tumour immunogenicity and enhance anticancer immune responses, including anti-GD2 antibodies; immune checkpoint inhibitors; drugs which enhance macrophage and natural killer T (NKT) cell function; modulation of the cyclic GMP-AMP synthase-stimulator of interferon genes pathway; and engineering neuroblastoma-targeting chimeric-antigen receptor-T cells. Some of these strategies have strong preclinical foundation and are being tested clinically, although none have demonstrated notable success in treating paediatric neuroblastoma to date. Recently, approaches to overcome heterogeneity of neuroblastoma tumours and treatment resistance are being explored. These include rational combination strategies with the aim of achieving synergy, such as dual targ
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet-
RT @jitcancer: New #JITC review: Neuroblastoma: an ongoing cold front for cancer immunotherapy https://t.co/a2DakIpZ9D https://t.co/ti287DF…
-
-
Mashup Score: 28Vaccinating against cancer: getting to prime time - 10 month(s) ago
Immunotherapies, such as immune checkpoint inhibitors, cellular therapies, and T-cell engagers, have fundamentally changed our approach to treating cancer. However, successes with cancer vaccines have been more difficult to realize. While vaccines against specific viruses have been widely adopted to prevent the development of cancer, only two vaccines can improve survival in advanced disease:…
Categories: Hem/Oncs, Latest HeadlinesTweet-
RT @jitcancer: New #JITC review: Vaccinating against cancer: getting to prime time https://t.co/2TMFmzCekH @gulleyj1 @lawfong https://t.co/…
-
-
Mashup Score: 12Vaccinating against cancer: getting to prime time - 10 month(s) ago
Immunotherapies, such as immune checkpoint inhibitors, cellular therapies, and T-cell engagers, have fundamentally changed our approach to treating cancer. However, successes with cancer vaccines have been more difficult to realize. While vaccines against specific viruses have been widely adopted to prevent the development of cancer, only two vaccines can improve survival in advanced disease:…
Categories: Hem/Oncs, Latest HeadlinesTweet-
RT @jitcancer: New #JITC review: Vaccinating against cancer: getting to prime time https://t.co/2TMFmzCekH @gulleyj1 @lawfong https://t.co/…
-
-
Mashup Score: 1Serpin B9 controls tumor cell killing by CAR T cells - 1 year(s) ago
Background Initial clinical responses with gene engineered chimeric antigen receptor (CAR) T cells in cancer patients are highly encouraging; however, primary resistance and also relapse may prevent durable remission in a substantial part of the patients. One of the underlying causes is the resistance mechanisms in cancer cells that limit effective killing by CAR T cells. CAR T cells exert their…
Categories: Latest Headlines, Oncologists2Tweet-
RT @jitcancer: New #JITC short report: Serpin B9 controls tumor cell killing by CAR T cells https://t.co/5w5rmLm9NZ @VictorPeperzak https:/…
-
-
Mashup Score: 13
In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a minimally invasive approach for the diagnosis and management of patients with cancer and as an enrichment tool in clinical trials. In recent years, the US Food and Drug Administration has approved multiple ctDNA-based companion diagnostic assays for the safe and effective use of targeted therapies and…
Categories: Hem/Oncs, Latest HeadlinesTweet-
RT @jitcancer: New #JITC review: Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/KnmKMVIZFV @PazVellanki…
-
-
Mashup Score: 11
In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a minimally invasive approach for the diagnosis and management of patients with cancer and as an enrichment tool in clinical trials. In recent years, the US Food and Drug Administration has approved multiple ctDNA-based companion diagnostic assays for the safe and effective use of targeted therapies and…
Categories: Latest Headlines, Oncologists2Tweet-
RT @jitcancer: New #JITC review: Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/KnmKMVIZFV @PazVellanki…
-
RT @jitcancer: New #JITC review: Biomarkers for response to TIL therapy: a comprehensive review https://t.co/LvHD0jOwHS @Vic_albarran @pbal…